×

Sign In

Search
Home

Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

By Thomson Reuters Oct 26, 2025 | 10:08 AM

(Reuters) -Swiss drugmaker Novartis AG is close to acquiring U.S. biotech Avidity Biosciences for over $70 per share, Bloomberg News reported on Sunday, citing a person familiar with the matter.

Reuters could not immediately confirm the report.

(Reporting by Dheeraj Kumar in Bengaluru; Editing by Aidan Lewis)

Syria arrests five suspects over shooting of US, Syrian troops in Palmyra

Bears WR Rome Odunze (foot) active vs. Browns

Canucks put Elias Pettersson on IR, activate Marco Rossi

Steelers TE Darnell Washington clears concussion protocol

New England teams embrace Brown after fatal on-campus mass shooting

Jimmy Lai, Hong Kong tycoon and democratic firebrand who stood up to China

Privacy Policy
Terms Of Service

Copyright © 2025. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.